

Clinical trials of statins for cardiovascular prevention in primary prevention

TrialResults-center www.trialresultscenter.org

1 statins

Trial	Treatments	Patients	Trials design and methods
pravastatin vs control			
FAST Fukuoka pravastatin , 2002 n=83/81 follow-up: 2 years	pravastatin 10 mg/day versus control group (diet alone)	asymptomatic hypercholesterolemic patients	open Japan
MEGA , 2006 [NCT00211705] n=3866/3966 follow-up: 5.3 y	pravastatin 10 mg daily (20 mg per day if the total cholesterol concentration did not decrease to 569 mmol/L or less) versus control	patients with hypercholesterolaemia (total cholesterol 569698 mmol/L) and no history of coronary heart disease or stroke	Parallel groups open, blind assessment Japan
fluvastatin vs placebo			
BCAPS , 2001 n=395/398 follow-up: 3.0 years	fluvastatin 40 mg once daily versus placebo	subjects who had carotid plaque but no symptoms of carotid artery disease	Factorial plan double-blind Sweden
pravastatin vs placebo			
CAIUS , 1996 n=151/154 follow-up: 3 years	pravastatin 40mg/d versus placebo	asymptomatic patients with hypercholesterolemia and at least one 1.3 <IMT <3.5 mm in the carotid arteries	Parallel groups double blind Italy
PMSG , 1993 n=530/532 follow-up: 26 weeks	pravastatin 20 mg once daily versus placebo	patients with hypercholesterolemia (serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter) and ≥ 2 additional risk factors for atherosclerotic coronary artery disease	Parallel groups double blind
PROSPER (primary prevention subgroup) , 2002 n=1584/1654 follow-up: 3.2 years	pravastatin 40mg/d versus placebo	men and women aged 70-82 years with a history of, or risk factors for, vascular disease; primary prevention subgroup	Parallel groups double blind Ecosse, Irlande, Pays bas
WOSCOPS , 1995 n=3302/3293 follow-up: 4.9 years	pravastatine 40 mg daily versus placebo	men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL)	Parallel groups double blind Scotland
rosuvastatin vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
HOPE 3 , 2016 [NCT00468923] n=6361/6344 follow-up: 5.6 years	rosuvastatin 10 mg per day versus placebo	subjects who did not have cardiovascular disease and were at intermediate risk	Factorial plan double-blind 21 countries
JUPITER , 2008 [NCT00239681] n=8901/8901 follow-up: median 1.9 year	rosuvastatin 20 mg daily versus placebo	apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)	Parallel groups double blind 26 countries
pravastatin vs usual care			
KLIS , 2000 n=3061/2579 follow-up: 5 years	pravastatin 10-20 mg/day versus conventional treatment	Japanese men aged 45-74 years with serum total cholesterol of >or = 220 mg/dl (5.69 mmol/l), primary prevention	Parallel groups open Japan

References

FAST Fukuoka pravastatin, 2002:

Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6 [11849859]

MEGA, 2006:

Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006 Sep 30;368:1155-63 [17011942]

Nakamura H [Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study)] Nippon Ronen Igakkai Zasshi 2009;46:18-21 [19246826]

BCAPS, 2001:

Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721-6 [11282901]

CAIUS, 1996:

Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Al G, Ventura A Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627-34 [9003110]

PMSG, 1993:

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993;72:1031-7 [8213583]

PROSPER (primary prevention subgroup), 2002:

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30 [12457784]

WOSCOPS, 1995:

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7 [7566020]

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1992;45:849-60 [1624967]

HOPE 3, 2016:

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Va Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016 Apr 2;: [27040132] 10.1056/NEJMoa1600176

JUPITER, 2008:

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008 Nov 9;: [1897196]

KLIS, 2000:

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.